Alder BioPharmaceuticals Appoints Timothy M. Whitaker, M.D., Chief Medical Officer

“We are very privileged to welcome Tim to Alder as our chief medical officer,” said Randall C. Schatzman, Ph.D., president and chief executive officer. “He is an accomplished executive responsible for establishing the strategic direction of clinical portfolios as well as achieving numerous global regulatory approvals of innovative therapeutics in the neuroscience space. Tim’s years of experience as a treating physician along with his extensive and deep experience in late stage drug development will enable him to build on Alder’s momentum to push ALD403 across the finish line for the prevention of chronic and frequent episodic migraine. His depth of knowledge will be invaluable as we continue our PROMISE 1 pivotal trial, initiate our second pivotal trial later this year, PROMISE 2, and plan and prepare a BLA submission with the FDA.”

Dr. Whitaker brings 20 years of experience in the pharmaceutical industry leading and managing global clinical development programs, including the strategic direction of multiple neuroscience clinical programs while achieving numerous global regulatory approvals. He joins Alder from Shire plc where he has held clinical development positions of increasing responsibility since 2004, most recently as the vice president and neuroscience therapeutic area head of global clinical development. During his tenure, he played a key role in developing the company as a world leader in specialty pharmaceuticals. From 1996 to 2004, Dr. Whitaker held the positions of associate director, director and senior director of clinical research and development, neuroscience divisions, at Wyeth. Prior to that, he held a variety of teaching and clinical appointments at the University of Vermont College of Medicine and the Medical Center Hospital of Vermont, including Associate Professor of Psychiatry and Director of the Psychopharmacology Clinic. He holds a bachelor’s degree from Duke University in Durham, N.C., and a medical degree from Wake Forest University School of Medicine in Winston-Salem, N.C. He completed a residency in psychiatry and a fellowship in clinical psychopharmacology at the Medical Center Hospital of Vermont in Burlington.